Work

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Year: 2015

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Blood

DOI: 10.1182/blood.v126.23.2563.2563

Authors: Jonathan Allen Webster, Raoul Tibes, Amanda Blackford, Lawrence Morris, Mrinal M Patnaik, Lihua Wang, Melanie Rebechi, Jacqueline Greer, Mark R Litzow, Larry Karnitz, Gary L. Rosner, Austin Doyle, Scott H. Kaufmann, Judith E Karp, B. Douglas Smith

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Mayo Clinic in Arizona, BMT Group (United States), Mayo Clinic, National Institutes of Health, National Cancer Institute

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2588779097

FWCI: 0.454

Cites:

Cited by: 2

Related to: 10